Repurposing CRH antagonists for the treatment of endometriosis
重新利用 CRH 拮抗剂治疗子宫内膜异位症
基本信息
- 批准号:10746682
- 负责人:
- 金额:$ 7.12万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-06-01 至 2024-04-30
- 项目状态:已结题
- 来源:
- 关键词:AddressAffectAftercareAlcoholismAnxietyAutologous TransplantationBrainChronicClinical TrialsCorticotropin-Releasing HormoneCorticotropin-Releasing Hormone ReceptorsDataDevelopmentDiseaseEffectivenessEndocrineEndometriumFacilities and Administrative CostsFertilityFutureGastrointestinal DiseasesGoalsHealth Care CostsHormonalHormone AntagonistsInfertilityInterventionLegal patentMarketingMasksMental DepressionModelingMood DisordersOperative Surgical ProceduresOvaryPainPeriodicityPeripheralPharmacological TreatmentPhase II Clinical TrialsQuality of lifeRattusRecurrenceRecurrent painResearchRoleStressSystemTherapeuticTissuesVesicleWagesWeightWithholding TreatmentWomanWorkagedalternative treatmentantagonistantalarminclinically relevantcommercializationdesigneffectiveness evaluationendometriosishypothalamic-pituitary-adrenal axisnovelpain-related disabilitypre-clinicalreceptorreproductiveresearch clinical testingresponse
项目摘要
PROJECT SUMMARY
Endometriosis is a chronic condition that affects 10% of reproductive-aged women worldwide. Unfortunately, up
to 59% of women with endometriosis do not respond to the available treatments and continue to suffer from
endometriosis-associated pain or recurrent pain after treatment cessation. Therefore, treatment alternatives that
deviate from the current therapeutic focus are urgently needed. The corticotrophin-releasing hormone receptor
type 1 (CRHR1) is a largely unexplored target. Corticotropin-releasing hormone (CRH), which activates the
CRHR1, is a critical molecule in the hypothalamic-pituitary-adrenal (HPA) axis that integrates stress and
endocrine responses both in the brain and in peripheral tissues. CRHR1 is abundant in the endometrium and
ovaries and has a role in developing endometriotic tissues, as demonstrated by the team's previous work.
CRHR1 antagonists were introduced into clinical trials for mood and gastrointestinal disorders with little to no
effect on those diseases and have never reached approval for commercial use. Previous work from the research
team demonstrated that short-term treatment with antalarmin, a CRHR1 antagonist frequently used in pre-clinical
experimentation, showed a 30% decrease in endometriosis development and a 60% decrease in the weight and
size of endometriosis vesicles. In continuation of these efforts, the overarching goal is to develop and
commercialize CRHR1 antagonists to treat endometriosis. The research team will focus on a compound recently
out of patent and reached Phase 2 clinical trials but was not effective for depression, anxiety, or alcoholism. To
begin addressing our goal, two specific aims were designed: on Aim 1, we will determine the effectiveness of a
clinically relevant CRHR1 antagonist for endometriosis treatment, including its effectiveness in decreasing
associated pain. Aim 2 will determine whether the CRHR1 antagonist affects the gonadal axis's cyclic hormonal
activity, independent of antiproliferative activity. Both aims will be done using the well-established
autotransplantation rat model of endometriosis, allowing for effective quantification and characterization of
endometriotic vesicles. Completed aims will reveal the optimal intervention for halting endometriosis progression
and predict possible mechanisms of action directly associated with the role of CRHR1 in the gonadal system.
Future efforts will focus on how the CRHR1 antagonism impacts fertility and fecundity, which are critical factors
to apply for re-introduction into clinical testing at the FDA. Bringing CRHR1 antagonists into the commercial field
have the strong potential of decreasing surgical interventions in women with endometriosis, resulting in
thousands of dollars saved in healthcare and indirect costs. The research team has identified the potential to
repurpose CRHR1 antagonists, but before being re-introduced into clinical trials, additional proof of action and
pre-clinical effectiveness is needed.
项目摘要
子宫内膜异位症是一种慢性疾病,影响全球10%的育龄妇女。不幸的是,
59%的子宫内膜异位症患者对现有的治疗没有反应,并继续遭受
治疗停止后,椎间盘突出相关疼痛或复发性疼痛。因此,
目前的治疗重点是迫切需要的。促肾上腺皮质激素释放激素受体
1型(CRHR 1)是一个很大程度上未开发的靶点。促肾上腺皮质激素释放激素(CRH),它激活
CRHR 1是下丘脑-垂体-肾上腺(HPA)轴中整合应激和
大脑和周围组织的内分泌反应。CRHR 1在子宫内膜中丰富,
卵巢,并在发育卵巢组织中发挥作用,正如该团队以前的工作所证明的那样。
CRHR 1拮抗剂被引入情绪和胃肠道疾病的临床试验,
对这些疾病的影响,从未获得商业用途的批准。以前的研究工作
研究小组证明,在临床前研究中经常使用的CRHR 1拮抗剂antalarmin的短期治疗
实验,显示子宫内膜异位症的发展减少了30%,体重减少了60%,
子宫内膜异位囊肿的大小。在继续这些努力的过程中,总体目标是发展和
将CRHR 1拮抗剂商业化以治疗子宫内膜异位症。研究小组最近将重点研究一种化合物
专利,并达到2期临床试验,但对抑郁症,焦虑症或酗酒无效。到
开始解决我们的目标,两个具体目标的设计:在目标1,我们将确定的有效性,
用于子宫内膜异位症治疗的临床相关CRHR 1拮抗剂,包括其降低
相关的疼痛。目的2将确定CRHR 1拮抗剂是否影响性腺轴的周期性激素分泌,
活性,独立于抗增殖活性。这两个目标都将使用完善的
子宫内膜异位症的自体移植大鼠模型,允许有效的定量和表征
囊泡。完成的目标将揭示阻止子宫内膜异位症进展的最佳干预措施
并预测与CRHR 1在性腺系统中的作用直接相关的可能作用机制。
未来的工作将集中在CRHR 1拮抗作用如何影响生育力和繁殖力,这是关键因素
申请重新进入FDA的临床试验CRHR 1拮抗剂进入商业领域
具有减少子宫内膜异位症妇女手术干预的强大潜力,
节省了数千美元的医疗保健和间接成本。研究小组已经确定了
重新使用CRHR 1拮抗剂,但在重新引入临床试验之前,需要额外的作用证据,
需要临床前的有效性。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Caroline B Appleyard其他文献
Caroline B Appleyard的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Caroline B Appleyard', 18)}}的其他基金
The Enteric Glia as a Possible Target for Symptom Relief in Endometriosis
肠胶质细胞作为缓解子宫内膜异位症症状的可能目标
- 批准号:
10625609 - 财政年份:2023
- 资助金额:
$ 7.12万 - 项目类别:
Repurposing CRH antagonists for the treatment of endometriosis
重新利用 CRH 拮抗剂治疗子宫内膜异位症
- 批准号:
10602801 - 财政年份:2022
- 资助金额:
$ 7.12万 - 项目类别:
Stress: Potential Impact on an Animal Model of Endometriosis
压力:对子宫内膜异位症动物模型的潜在影响
- 批准号:
8468876 - 财政年份:2012
- 资助金额:
$ 7.12万 - 项目类别:
THE ROLE OF BACTERIAL PEPTIDES IN CHRONIC INTESTINAL INFLAMMATION
细菌肽在慢性肠道炎症中的作用
- 批准号:
8357063 - 财政年份:2011
- 资助金额:
$ 7.12万 - 项目类别:
Stress: Potential Impact on an Animal Model of Endometriosis
压力:对子宫内膜异位症动物模型的潜在影响
- 批准号:
8180413 - 财政年份:2011
- 资助金额:
$ 7.12万 - 项目类别:
相似海外基金
RII Track-4:NSF: From the Ground Up to the Air Above Coastal Dunes: How Groundwater and Evaporation Affect the Mechanism of Wind Erosion
RII Track-4:NSF:从地面到沿海沙丘上方的空气:地下水和蒸发如何影响风蚀机制
- 批准号:
2327346 - 财政年份:2024
- 资助金额:
$ 7.12万 - 项目类别:
Standard Grant
BRC-BIO: Establishing Astrangia poculata as a study system to understand how multi-partner symbiotic interactions affect pathogen response in cnidarians
BRC-BIO:建立 Astrangia poculata 作为研究系统,以了解多伙伴共生相互作用如何影响刺胞动物的病原体反应
- 批准号:
2312555 - 财政年份:2024
- 资助金额:
$ 7.12万 - 项目类别:
Standard Grant
How Does Particle Material Properties Insoluble and Partially Soluble Affect Sensory Perception Of Fat based Products
不溶性和部分可溶的颗粒材料特性如何影响脂肪基产品的感官知觉
- 批准号:
BB/Z514391/1 - 财政年份:2024
- 资助金额:
$ 7.12万 - 项目类别:
Training Grant
Graduating in Austerity: Do Welfare Cuts Affect the Career Path of University Students?
紧缩毕业:福利削减会影响大学生的职业道路吗?
- 批准号:
ES/Z502595/1 - 财政年份:2024
- 资助金额:
$ 7.12万 - 项目类别:
Fellowship
Insecure lives and the policy disconnect: How multiple insecurities affect Levelling Up and what joined-up policy can do to help
不安全的生活和政策脱节:多种不安全因素如何影响升级以及联合政策可以提供哪些帮助
- 批准号:
ES/Z000149/1 - 财政年份:2024
- 资助金额:
$ 7.12万 - 项目类别:
Research Grant
感性個人差指標 Affect-X の構築とビスポークAIサービスの基盤確立
建立个人敏感度指数 Affect-X 并为定制人工智能服务奠定基础
- 批准号:
23K24936 - 财政年份:2024
- 资助金额:
$ 7.12万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
How does metal binding affect the function of proteins targeted by a devastating pathogen of cereal crops?
金属结合如何影响谷类作物毁灭性病原体靶向的蛋白质的功能?
- 批准号:
2901648 - 财政年份:2024
- 资助金额:
$ 7.12万 - 项目类别:
Studentship
ERI: Developing a Trust-supporting Design Framework with Affect for Human-AI Collaboration
ERI:开发一个支持信任的设计框架,影响人类与人工智能的协作
- 批准号:
2301846 - 财政年份:2023
- 资助金额:
$ 7.12万 - 项目类别:
Standard Grant
Investigating how double-negative T cells affect anti-leukemic and GvHD-inducing activities of conventional T cells
研究双阴性 T 细胞如何影响传统 T 细胞的抗白血病和 GvHD 诱导活性
- 批准号:
488039 - 财政年份:2023
- 资助金额:
$ 7.12万 - 项目类别:
Operating Grants
How motor impairments due to neurodegenerative diseases affect masticatory movements
神经退行性疾病引起的运动障碍如何影响咀嚼运动
- 批准号:
23K16076 - 财政年份:2023
- 资助金额:
$ 7.12万 - 项目类别:
Grant-in-Aid for Early-Career Scientists